AMENDMENTS TO THE CLAIMS

1-15. (CANCELED)

16. (CURRENTLY AMENDED) An oral dosage form comprising:

(a) an effective amount of an alkalizing agent; and

(b) multiparticulates wherein said multiparticulates comprise (i) about 20 % to about 75% azithromycin, and (ii) ~~a wax,~~ about 25% to about 80% of a glyceride ~~or a mixture thereof~~ which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate or a mixture thereof; and (iii) a poloxamer.

17-24. (CANCELED)

25. (CURRENTLY AMENDED) An oral dosage form of claim ~~24~~ 16 wherein the poloxamer comprises poloxamer 407.

26. (CURRENTLY AMENDED) An oral dosage form of ~~Claim 25~~ claim 16 wherein the alkalizing agent comprises a bicarbonate, a phosphate, a metal hydroxide, a metal oxide or a combination thereof.

27. (ORIGINAL) An oral dosage form of Claim 26 wherein the alkalizing agent comprises tribasic sodium phosphate and magnesium hydroxide.

28. (PREVIOUSLY PRESENTED) An oral dosage form of claim 26 further comprising about 250 mgA to about 7 gA of azithromycin.

29. (ORIGINAL) An oral dosage form of Claim 28 further comprising about 1.5 gA to about 4 gA of azithromycin.

30. (ORIGINAL) An oral dosage form of Claim 28 further comprising 1.8 to 2.2 gA of

azithromycin.

31. (ORIGINAL) An azithromycin oral dosage form, comprising:

(a) at least about 200 mg of tribasic sodium phosphate; and

(b) multiparticulates, wherein said multiparticulates comprise (i) azithromycin, (ii) a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and (iii) poloxamer 407, and wherein said dosage form contains about 1.5 gA to about 4 gA of azithromycin.

32. (ORIGINAL) An oral dosage form of Claim 31, further comprising at least about 100 mg of magnesium oxide.

33. (ORIGINAL) An oral dosage form of Claim 31, comprising:

(a) 300 mg to 400 mg of tribasic sodium phosphate;

(b) 200 mg to 300 mg of magnesium hydroxide; and

(c) multiparticulates, wherein said multiparticulates comprise (i) azithromycin, (ii) a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and (iii) poloxamer 407,

and wherein said dosage form contains about 1.5 gA to about 4 gA of azithromycin.

34. (CURRENTLY AMENDED) An oral dosage form of ~~Claims 31-33~~ claim 31 further comprising 1.8 to 2.2 gA of azithromycin.

35. (ORIGINAL) An oral dosage form of Claim 34 wherein said azithromycin is azithromycin dihydrate.

36. (PREVIOUSLY PRESENTED) An oral dosage form of claim 16 wherein said azithromycin is azithromycin dihydrate.

37. (PREVIOUSLY PRESENTED) An oral dosage form of claim 26 wherein said

azithromycin is at least 70 wt% crystalline.

38. (PREVIOUSLY PRESENTED) An oral dosage form of claim 26 wherein said oral dosage form is a powder for oral suspension, a unit dose packet, an oral suspension, a tablet or a capsule.

39 – 48. (CANCELED)

49. (PREVIOUSLY PRESENTED) A method for reducing the frequency of gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering oral dosage form of claim 16 to said mammal wherein the frequency of gastrointestinal side effects is reduced as compared to the frequency experienced when administering an equal dose of azithromycin without said alkalizing agent.

50. (ORIGINAL) A method of Claim 49 wherein said mammal is a human.

51. (ORIGINAL) A method of Claim 50 further comprising administering between about 250 mgA and about 7 gA of azithromycin to said human.

52. (ORIGINAL) A method of Claim 51 wherein the azithromycin is administered in a single dose.

53. (ORIGINAL) A method of Claim 52 further comprising administering between about 1.5 and about 4 gA of azithromycin.

54. (ORIGINAL) A method of Claim 52 further comprising administering between about 1.5 and about 3 gA of azithromycin.

55. (ORIGINAL) A method of Claim 52 further comprising administering between 1.8 and 2.2 gA of azithromycin to said human in a single dose.

56. (ORIGINAL) A method of Claim 50 further comprising administering between 30 mgA/kg and 90 mgA /kg of azithromycin to a human, wherein said human is a child weighing 30 kg or less.

57. (ORIGINAL) A method of Claim 56 wherein the azithromycin is administered in a single dose.

58. (ORIGINAL) A method of Claim 57 further comprising administering between 45 mgA/kg and 75 mgA /kg of azithromycin to a child weighing 30 kg or less.

59. (ORIGINAL) A method of Claim 57 further comprising administering about 60 mgA/kg of azithromycin to a child weighing 30 kg or less.

60. (PREVIOUSLY PRESENTED) A method of claim 49 wherein the alkalizing agent further comprises a bicarbonate, a phosphate, a metal hydroxide, a metal oxide, or a combination thereof.

61. (ORIGINAL) A method of Claim 60 wherein the alkalizing agent comprises tribasic sodium phosphate and magnesium hydroxide.

62. (ORIGINAL) A method of Claim 60 wherein said azithromycin comprises an immediate release form of azithromycin.

63. (ORIGINAL) A method of Claim 60 wherein said azithromycin comprises a sustained release form of azithromycin.

64. (ORIGINAL) A method of Claim 60 wherein said azithromycin comprises azithromycin multiparticulates.

65. (ORIGINAL) A method of Claim 64 wherein said azithromycin multiparticulates

comprise:

(a) azithromycin; and

(b) a pharmaceutically acceptable carrier.

66-75. (CANCELED)

76. (PREVIOUSLY PRESENTED) A method of treating a bacterial or protozoal infection in a mammal in need thereof comprising administering to said mammal a single dose of an oral dosage form of claim 16.

77. (ORIGINAL) A method of Claim 76 wherein said mammal is a human.

78. (ORIGINAL) A method of Claim 77 further comprising administering between about 250 mgA and about 7 gA of azithromycin to said human.

79. (ORIGINAL) A method of Claim 78 wherein the azithromycin is administered in a single dose.

80. (ORIGINAL) A method of Claim 79 further comprising administering between about 1.5 and about 4 gA of azithromycin to said human.

81. (ORIGINAL) A method of Claim 79 further comprising administering between about 1.5 and about 3 gA of azithromycin to said human.

82. (ORIGINAL) A method of Claim 79 further comprising administering 1.8 gA to 2.2 gA of azithromycin to said human.

83. (ORIGINAL) A method of Claim 77 further comprising administering between 30 mgA/kg and 90 mgA /kg of azithromycin to said human, wherein said human is a child weighing 30 kg or less.

84. (ORIGINAL) A method of Claim 77 wherein the azithromycin is administered in a single dose.

85. (ORIGINAL) A method of Claim 84 further comprising administering between 45 mgA/kg and 75 mgA /kg of azithromycin to a child weighing 30 kg or less.

86. (ORIGINAL) A method of Claim 84 further comprising administering 60 mgA/kg of azithromycin to a child weighing 30 kg or less.

87. (CURRENTLY AMENDED) A method of ~~Claims 76-86~~ claim 76 wherein the alkalizing agent comprises a bicarbonate, a phosphate, a metal hydroxide, a metal oxide, or a combination thereof.

88. (ORIGINAL) A method of Claim 87 wherein the alkalizing agent comprises tribasic sodium phosphate.

89. (ORIGINAL) A method of Claim 88 wherein the alkalizing agent further comprises magnesium hydroxide.

90. (ORIGINAL) A method of Claim 87 wherein said azithromycin comprises an immediate release form of azithromycin.

91. (ORIGINAL) A method of Claim 87 wherein said azithromycin comprises a sustained release form of azithromycin.

92-114. (CANCELED)